ABHISHEK KANUGO*  
SVKM NMIMS School of Pharmacy and Technology Management, Shirpur, Dhule, India 425405  
Email: abhi.kanugo09@gmail.com  
Received: 22 Aug 2020, Revised and Accepted: 30 Sep 2020

ABSTRACT

The current article aims with the introduction of newer solubility enhancing technique as Liquisolid-pellet. The majority of newly invented molecules comes under the biopharmaceutical classification system (BCS) Class II, IV indicating poor solubility and thereby poor bioavailability. Liquisolid Compaq is one of the solubility enhancement techniques used for improving solubility and dissolution of the molecule by incorporating non-volatile solvent followed by carrier and coating agents. However, this technique is only applicable to potent molecules as a higher dose resulted in inconvenience to the patient and difficult to swallow. Another drawback of this method is not suitable for pilot plant-scale up. Liquisolid pellet technique overcoming all limitations of Liquisolid Compaq and offers good compaction, flowability, dose accuracy, less gastric irritations, and better bioavailability. In the Liquisolid-Pellet technique, powdered material received from Liquisolid Compaq is further moistened with granulating fluid to provide enough plasticity. The material is subjected to extrusion using an extruder to generate extrudates. The extrudates are placed under the spheronizer to form spherical particles as Pellets. The pellets are mainly prepared by extrusion-spheronization and hence, articles elaborate details technique overcoming all limitations of Liquisolid Compaq and offers good compaction, flowability, dose accuracy, less gastric irritations, and better bioavailability.

Keywords: Solubility enhancement, Liquisolid technique, Liquisolid-Pellet, Pellet, Extrusion-spheronization, Bioavailability

INTRODUCTION

Most preference allotted to solid orals owing to their convenience, compliance, uniformity, and stability [1]. Several characteristics of the active ingredient and functional excipients like solubility, dissolution rate, presystemic metabolism, etc. have a strong impact on their bioavailability [2]. Most of the newly invented molecules, around 90 % and 40 % of approved active pharmaceutical ingredients, showed poor solubility in water and ultimately low bioavailability [3]. Hence, one of the simplest attempts to improve the bioavailability is to accelerate their solubility and dissolution rate. Drug permeability is a property that affects oral bioavailability. The outcome of drug design and development introduced the molecules with high lipophilic and molecular weight characteristics, which failed to show good solubility and, ultimately bioavailability [4]. The active ingredient is considered as highly soluble when their highest dose is solubilized in a solvent of 250 ml at the entire pH range (1-7), reported by FDA and BCS. Moreover, the active ingredient is categorized as permeable when its absorption across the intestine will be 90 percent. BCS reported that there is a definite relationship between dissolution and bioavailability observed outside and inside of the body, termed as IVIVC. Rely on solubility and permeability, active ingredient categorized into four classes and out of them, class II and IV is a good candidate for improving the bioavailability [5-7]. Several techniques have been implemented for improving the solubility and bioavailability depicted in table 1 [8].

| Approaches and dissolution | Techniques | References |
|---------------------------|------------|-----------|
| Enhancing solubility and dissolution | Micronization | [9] |
| | Nanonisation | [10] |
| | Supercritical fluid recrystallization | [11] |
| | Spray freezing into liquids | [12] |
| | Using surfactants | [13] |
| | Using salt form | [14] |
| | Using precipitation inhibitors | [15] |
| | Solid Dispersion | [16] |
| | Using cyclodextrins | [17] |
| Enhancing permeability | Microemulsions, Self-micro emulsifying drug delivery system (SMEDDS), self-nanoemulsifying drug delivery system (SNEDDS) | [18] |
| | Solid lipid nanoparticles (SLN) | [19] |
| | Nanostructured lipid carrier (NLC) | [20] |
| | Liposomes | [21] |
| | Penetration enhancers | [22] |
| Enhancing stability | Enteric coating | [23] |
| | Using metabolism inhibitors | [24] |

LIQUISOLID-PELLETS TECHNIQUE: A RECENT TECHNIQUE FOR ENHANCING SOLUBILITY AND BIOAVAILABILITY OF DRUGS

The Liquisolid concept was first demonstrated by Spiraeas and his team described that the active ingredients mostly exist as powder and hydrophobic. Their solubility was improved by incorporating a liquid that is non-volatile to make it available as a solution or suspension [26-27]. Excipients functioning as a carrier and having good adsorption characteristics with porosity should be preferred.
and added to the above solution or suspension. Moreover, the incorporation of a coating agent in solution or suspension improved the flow behavior of powder and make it available as directly compressible to formulate as tablets [28]. The non-volatile solvent should be selected based on the highest solubility of the active ingredient in the solvent. Greater solubility of active ingredient resulted in improved dissolution and bioavailability [29]. One of the limitations of the Liquisolid technique is that it applies only for a minimum dose of drugs. Active ingredients are having a weight of more than 400 mg found to be poor candidates, as they required a large amount of solvent for solubilization. The addition of more amount of solvent needs an excess quantity of carrier and coating agent. This ultimately resulted in a higher weight of the finished product, which is difficult to swallow. Hence, this method is not suitable for high doses [30].

**Fig. 1: Manufacturing steps involved in liquisolid technique**

**Liquisolid pellet technique**

Matthew Lam et al. 2019 developed the Liqui-pellet, a new solubility enhancing technique for enhancing oral bioavailability of BCS class II/IV drugs. Liqui-pellet comes from combining the concept of the Liquisolid Compaq technique with pelletization technology. Firstly, it was postulated that the Liqui-pellet was different from the Liquisolid technique from the definition point of view [31]. The Liqui-pellet cannot be considered as the Liquisolid Compaq technique, as it is based on the concept of powdered material, which is moist and not as freely flowable. Whereas, Liqui-pellet et al. showed good flowability characteristics and available in the form of pellets. Liqui-pellet technique overcomes the limitations of Liquisolid Compaq, where a higher dose can also be suitable for improving the solubility and final weight is quite low [32].

Matthew Lam and his coworkers provided further clarification in 2020, that the Liquisolid-pellet were different from the Liqui-pellets. Spireas in his patent, described that the Liquisolid powders should be flowable by adding more carriers, which in turn reduces load factor and makes the final dosage form, which was very bulky. As it contains a high load factor, a wet mass system, which is a non-flowable powder, should be produced, which was different from the Liquisolid system, which is a flowable powder. Hence, on that basis, differentiated the terms, the Liqui-pellet uses the Liqui-mass system, whereas Liquisolid-pellet uses the Liquisolid system [33].

**Fig. 2: Advantages of liquisolid-pellet technology**

**Formulation components of the liquisolid-pellet technique**

1. Selection of drug candidate: Drugs with low oral bioavailability are a good candidate for this technique. Drug candidates classified as class II/IV as per BCS is to
be chosen for enhancement of bioavailability. E.g. Carbamazepine, Naproxen and Ritonavir, etc. [34-36].

2. Selection of Non-volatile solvent (NVS):
They possess inertness, high boiling point, and lower viscosity. Generally, the less viscous liquid should be preferred as it requires a minimum amount of carrier and coating agent to generate free-flowing powder as well as minimizes tablet weight. E.g. Polyethylene glycol 200/400/600, propylene glycol, Polysorbate 20/80, Span, Labrafil, Labrasol and Kolliphor EL, etc. [37-40].

3. Selection of Carrier material:
Carrier material should be incorporated for compression enhancing. These materials are porous with enough soaking tendency. Several derivatives of cellulose, starch, lactose are used as carrier material. Carrier material should be selected based on its absorption capacity and inertness with drugs.

4. Selection of coating material:
Coating material should have good flow characteristics and possess high adsorptive property. Various grades of silica are widely used for coating. They are primarily utilized for adsorption behavior and thereby providing the material as freely flowable [39-40].

5. Additional excipients:
Liquisolid-Pellet system requires additional excipients used as Disintegrants, directly compressible excipients, and lubricants, etc. [41-43].

**Manufacturing process for liquisolid-pellet technique**
The manufacturing process involved in the Liquisolid-Pellet technique involves the utilization of both processes as the Liquisolid technique followed by extrusion-Spheronization. According to the solubility of the drug, non-volatile solvents should be chosen. The active ingredients should be rapidly dispersed in a non-volatile solvent, which results in the formation of liquid medication or as a drug solution. This drug solution was sonicated for about 10-15 min until a clear homogenous solution is obtained. Micronized cellulose should be mixed with solution or suspension as a carrier, which is also a filler and binder for further process of extrusion-Spheronization. Finally, cross-povidone is incorporated as a disintegrating and coating agent, which gives, moisten powder material as Liquisolid system [44].

The prepared Liquisolid mixture is then further gradually wetted with solvent so that enough plasticity is generated for extrusion-Spheronization. The wet mass is then rapidly undergoing extrusion using an extruder through a desired mesh. The extrudates obtained is then quickly transferred to Spheronization, so that good quality of pellets will be formed. The formed pellets are then dried in a fluidized bed dryer for about 10-20 min. The dried pellets are further compressed to form tablets or filled in capsules [45].

**Extrusion-spheronization**
Extrusion-spheronization is the most widely used technique for the manufacturing of pellets. Pellets are defined as “small, free-flowing, spherical units made up of fine powders or granules of bulk drugs and excipients by involving mostly extrusion and spheronization.” The prepared pellets can be utilized for rapid release or controlled release. One of the big advantages of extrusion-spheronization technology is that a large number of active ingredients can be loaded in pellets as compared with other techniques for pellets production [46].

**Manufacturing of pellets via extrusion-spheronization**
The process of extrusion-spheronization involves several steps as,

a. The material utilized for processing should be dried completely for further mixing to get uniformity in powder dispersion.

b. Then the material is wetted to create enough plastic wet load or mass.

c. The obtained wet mass further undergoes extrusion to generate rod-shaped particles.

d. These rod-shaped particles further spheronize so that spherical particles are generated.

e. The spherical particles are further dried and screen to achieve the desired particle size [47].

**Types of extruders**
Extruders are generally composed of 2 portions; the delivery and die system. The delivery system responsible for the movement of material and mixing of the material, whereas die systems helps in generating the material in the desired shape. Based on the feed mechanism, extruders are classified as follows.

1. Screw feed extruder containing axial, dome, and radial type

2. Gravity feed extruder consisting of cylinder roll, gear roll, and radial type.

3. Piston feed or Ram extruder

4. Screen or Basket extruder

5. Roll extruder [48]

**Screw feed extruders**
Make use of the screw for creating pressure required to propel the material so that it will flow. Rely on the design, solid substances move via several openings, thereby resulted in similar strands, which are commonly known as extrudates. They composed of single or twin helical screws revolving in a barrel and hence shifted the solid material from the hopper to the die. The die system is consisting of a thin steel plate with several holes and available in the form of an axial or radial screw feeder.
**Fig. 4: Steps involved in manufacturing of pellets**

**Table 2: Types of screw extruder and their specifications**

| S. No. | Screw extruder | Description | Advantages | Features | Reference |
|--------|----------------|-------------|------------|----------|-----------|
| 1      | Axial          | Mostly employed in pellet formation with size ranges from 400 µ to 2000 µ. Provides a minimum output of 250 g and a maximum of 150 kg/h. | Axial mesh with feed hopper and pressing cams and a screws Available as a screen along with hopper and compressing cams with a screw. Rotates at 20-100 rpm. Available at touch screen with traceability Easy to operate and clean. Operated at 40-100 rpm. Available as pressing cams with screw and hopper. | Build the main part with stainless steel 316 grade and rest with 304. The maximum product recovered up to 100 %. Created low fines after the operation Available in several axial meshes as 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1 and 1.2 mm. Similar to axial. | [49] |
| 2      | Dome           | The Dome extruder presses 300-1200 µ of particle sizes. Providing an output of a minimum of 100 to 200 g and max of 6 kg/h. | | | [49] |
| 3      | Radial         | Capable of producing an extrudate of 400 to 1500 µ particles. | Operated at speed of 20-100 rpm. | Similar to axial. | [49] |

**Gravity feed extruders**

They composed with moving gear and cylinder, which further merged into roll extruders. They utilize rollers, which create pressure on the material and generates extrudate. These extruders generated extrudate by exerting pressure on the wetted mass by utilizing two rollers. The cylinder type extruder with two rollers available in the form of a cylinder as solid and other with a hollow cavity to generate dies. Whereas gear type extruders are also containing rollers with gear. The third type of extruder is radial in which arms are rotated so that wetted mass passed with pressure. Due to the presence of a rotating blade, they tear the wetted material and capable of generating extrudate. These are differentiated from gravity and screw extruder in the aspect of not using compression before extrusion.

**Ram extruder**

This type of extruder is based on the concept of utilizing a ram or plunger alternatively to screw. In this type of extruder, the piston displaces and drive the material towards the die at the opposite end [50].

**Screen or basket extruder**

Screen or sieve type extruders composing a chamber that grip the material and enabled them to extrude. The spinning section pushes the material through a porous screen or sieve, thereby producing tiny or long extrudates. The formation of these extrudates relies on the presence of moisture content. Whereas basket extruder differs from the screen extruder as it is placed horizontally and vertically, respectively.

**Roll extruder**

It is also known as Pellets mill, worked by suppling materials between a ring die or plate and roller. The designing of the roll extruder consisting of a ring die plate that revolves inside of the cylindrical die chamber and each one revolving on a fixed plane. Every part which is capable of spinning is in the same directions. The substances are added to the interior surface of the die and hence rollers compress them outsides.

**Impact of factors on extrusion-spheronization**

**Moisture content**

The amount of water or moisture available in the solid materials determines the effective processing of extrusion as well as the quality of pellet formation. Enough amount of moisture content is desirable during extrusion as a lower amount resulted in the generation of dust particles during spheronization. If the moisture content is beyond their limits, then it also affects the process by forming agglomerates. The moisture content in the material also affects the density of spherical particles, its surface characteristics and the torque of an extruder [52]. Lustig-Gustafsson *et al.* reported that the quantity of water necessary for pellet formation depended on the active ingredient and its particle size [53].
Types of spheronizers

Table 3: Spheronizer and its features

| S. No. | Types                      | Salient features                                      | Reference |
|--------|----------------------------|-------------------------------------------------------|-----------|
| 1      | Micro spheronizer          | Applicable only for small labs and trial purpose      | [54]      |
| 2      | Multi bowl spheronizer 250 | Design with the intention of laboratory-scale indicating minimum quantity. Capacity: ranges from 1 g to 1 kg Used along with screw extruder 20 and mini screw extruder | [51]      |
| 3      | Model 380 spheronizer      | Implemented for producing smooth and spherical pellets Capacity: ranges from 0.5 kg to 4 kg | [51]      |
| 4      | Model 500 spheronizer      | Implemented for producing smooth and spherical pellets Capacity: ranges from 1 kg to 11 kg | [51]      |
| 5      | Model 700 spheronizer      | Produces smooth and regular pellets Capacity ranges from 5 kg to 25 kg. | [51]      |
| 6      | Model 700 spin spheronizer | Applicable for continuous production due to the presence of dual drum | [51]      |

Granulating fluids

The most widely used solvent for granulation is distilled water. Additionally, alcohol or a mixture with water is also recommended. Dreu et al. observed that the quality of pellet formation changes according to the addition of granulating fluids as tested using water and a combination of water/alcohol. The mechanical and structural characteristics of pellets strongly dependent on the type of granulating fluids. This is mainly due to the affection of contraction driving and counteracting forces during drying conditions [54].

Excipient

The excipients incorporated as carrier and coating agent as well as for further processing conditions of extrusion, have a strong impact on pellets formation. Fielden et al. evaluated lactose powder when used in two different grades as coarse and fine during extrusion showed variation in the formation of the spherical shape of pellets. Levis et al. evaluated several grades of microcrystalline cellulose as single ultrafine (A), in combination with SLS (B) and another PH-101 grade (C). The material labeled as A and B showed better yields than C in the formulation of indomethacin pellets [55]. Rojas et al. reported that MCC II exhibiting good pellet formation properties with good flowability, enough mechanical strength, and less friability [56]. Sometimes, MCC is not used during extrusion-spheronization as it tends to retard the release of the poorly water-soluble active ingredients, not compatible with active moiety and adsorption tendency. Hence, alternatively cellulose derivatives, HPMC, HPC, PEO, cross-linked PVP as well as some synthetic polymers [52].

Extruders

The selection of extruder is important for availing good quality of pellets. The displacement forces observed in the Ram extruders are found to be better than in gravity feed extruders. The pressure or strength needed to eject the wetted material through ram extruder decreased upon the addition of water. Hence, lowering the water content resulted in increasing ejection, thereby influencing the quality of spherical units. Small size pellets are generally achieved using a screen extruder as compared with ram extruders. In the case of roll type extruders, criteria for deciding discharge flowing speed, the pressure applied on the screen, and roller torque rely on the spacing available between roller blade and screen as well as roller turning speed. An axial type screw extruders are capable of generating highly dense particles comparatively with radial screw extruders. Sonaglio et al. developed paracetamol pellets by using an axial and radial type of screw extruder and reported that alterations in temperature and time required for extrusion [57] found to be higher in an axial type.

Extrusion screen

The die aperture present in the screen or plate is available in various designs. The type of desired products depending on the selection of the screen or the plate. When a thick plate or screen is employed, it generates dense products. The thin screens or plates are generally straight. The aperture size ranges from 0.5 to 1.5 mm and is considered as standard.

Extrusion speed

The cumulative yield of any extruder depends on its speed. Generally, higher yield is expected from any kind of extruders but excessive high speed affects the quality of spherical particles.

Extrusion temperature

Fielden et al. evaluated the effects of fluid and MCC by using thermal methods. The studies indicated that water or fluid utilized as granulating fluids is available in the free form and easily converted into the vapors by the process of evaporation, thereby sometimes affects the final products [58].

Friction plate

It is one of the most important segments of spheronizer having a narrowed surface that is responsible for providing frictional forces [59]. There are two different types of furrow geometry observed as cross-hatch and radial, which work effectively. The more controlled action was observed in the radial disc, but not found to be suitable for giant diameter discs. The most widely used disc in spheronizer is square cross-hatched square design, in which developing surfaces are overlaid with a grid of truncated tomb. The material of extrudates with a diameter up to 0.8 mm is carried out using 2 mm pitch plate and for 3 mm diameter, 3 mm pitch plate is recommended.

Disk speed and load

During spheronization, disk speed and load should be remaining optimum to achieve better output. If the speed remains low, then extrudates will not densify and spherical units not formed. Whereas excessive speed than recommended resulted in higher pressure on the granular materials, lower porosity, increased breaking tendency of granules, pressing of particles. Particularly the revolving speed for disks having less than 500 mm diameter should be operated at about 200 to 1000 rpm. The optimum speed relies on the properties of the material being used and their particle size. Generally, for smaller particles, higher speed is chosen and for larger ones, lowers speed. It is recommended that, during the initiation of Spheronization, velocity is kept higher and later will be slower. The quantity of load incorporated is dependent on machine capacity and size. A machine with 380 mm diameter, the material is approx. 4 liters, also depends on the density of that material.

Product-related parameters

The materials subjected to Spheronization must have enough plasticity to permit distortion to take place during striking. Some of the extrudates bearing high cohesive forces, which takes a longer time to break and increased processing time.  

Other factors

The rheology of the material can be altered by using binders, lubricants, or by modifying mixing time. In critical cases, Mixer Torque Rheometer found very useful for measuring the rheology of the material easily and immediately. A sufficient quantity of binders must be added, which provides robustness to the granules and...
minimizes the formation of dusty particles during spheronization. Excessive binder concentration resulted in the hardening of granules and created difficulties in spherical units [50, 61].

CONCLUSION
Oral drug delivery is mostly preferred in pharmaceutical developments due to its several advantages. Dissolution is the rate-limiting step towards achieving oral absorption and bioavailability. Liquisolid Compaq is such a technique utilized for the enhancement of poorly soluble active ingredient by incorporating non-volatile solvent. However, this technique can’t utilize for drug candidates above 400 mg of dose, as higher dose resulted in large size of the dosage form, which is difficult to administer as well as difficult to scale up in the Pharmaceutical industry. Hence to provide the benefits of this technique and overcoming its limitations, the Liquisolid-Pellet technique is introduced. Liquisolid-Pellet technique has no such restrictions of dose of drugs and highly scales up and more beneficial. This technique generated good quality of pellets using the concept of Extrusion-Spheronization, so before proceeding to this technique, researchers have to understand the impact of various factors affecting extrusion-spheronization.

FUNDING
Nil

AUTHORS CONTRIBUTIONS
All the author have contributed equally.

CONFLICTS OF INTERESTS
Declared none

REFERENCES
1. Tadikonda RR, Shatri N, Chella N. Use of the liquid solid compaq technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012;2:50-28.
2. Gajjar AK, Savjani KT, Savjani JK. Drug solubility: importance and techniques. ISRN; 2012. p. 1-10.
3. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B 2015;5:44-52.
4. Hasan SM, Butt S. Directly compressed rosuvatatin calcium tablets that offer hydrotropic and micellar solubilization for improved dissolution rate and extent of drug release. Saudi Pharm J 2019;27:614-28.
5. Butania SB, Prajapata MD, Gohel MC. Liquisolid: a promising technique to improve dissolution efficiency and bioavailability of poorly water-soluble nimodipine. J Drug Delivery Sci Tech 2019;5:3:101135.
6. Surti N, Pipaliya RM, Patel DS. Liquisolid tablets for dissolution enhancement of a hypolipidemic drug. Int J Pharm Sci 2015;77:290-8.
7. Bonthagarala B, Dasari V, Kotra V. Quality-by-design based development and characterization of pioglitazone loaded liquid solid compact tablets with improved biopharmaceutical attributes. J Drug Delivery Sci Tech 2019;51:3:45-55.
8. Brahmanakar DM, Jaiswal SB. Bioavailability and bioequivalence: biopharmaceuticals and pharmacokinetics a treatise: Vallabh prakashan; 2009. p. 349-62.
9. Kaarashima M, Ikeda Y, Sano N. Enhanced pulmonary absorption of poorly soluble iraconazole by micronized cocystal dry powder formulations. Eur J Pharm Biopharm 2017;115:65-72.
10. Lee BJ, Kim D, Park C. Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjunct for poorly water-soluble drugs via self-assembly and nanonization. Int J Pharm 2020;575:119892.
11. Elisabeth B, Masmoudi Y, Mouahid A. Current situation and perspectives in drug formulation by using supercritical fluid technology. J Supercritical Fluids 2018;134:274-83.
12. Hu J, Johnston KP, Williams RO. Spray freezing into liquid particle engineering technique to enhance the dissolution of poorly water drugs: organic solvent versus organic/aqueous co-solvent system. Eur J Pharm Sci 2005;20:295-303.
13. Zhang C, Zi P, Zhang C. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant-soluplus. Eur J Pharm Sci 2019;134:233-45.
14. Chopra D, Suresh A, Mondal P. Improving solubility and intrinsic dissolution rate of ofloxcin API through salt formation via mechanochemical synthesis with diaphenic acid. J Mol Str 2020;2:128806.
15. Saal C, Price D, Nair A. Incorporation of HPMCAS during loading of glibenclamide onto mesoporous silica improves dissolution and inhibits precipitation. Eur J Pharm Sci 2020;41:105131.
16. Lewis SA, Muwa A, Laksman D. In vitro-in silico evaluation of apremilast solid dispersion prepared via corotating twin-screw extruder. J Drug Delivery Sci Tech 2020;59:101844.
17. Ge L, Webster T, Han H. A soluplus/poloxamer 407-based self nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability. Nanomed Nano Tech Bio Med 2020;27:102199.
18. Bergonzzi MC, Righeschi C, Isacci B. Enhanced curcumin permeability by SLN formulation: the PAMPA approach. Food SciTech 2016;60:475-83.
19. Vavla P, Shevurald G. Solidified nanostructured lipid carrier for enhancing the oral bioavailability of ezetimibe. J Drug Delivery Sci Tech 2019;53:101211.
20. Jan Y, Xiaoai, Lihua L. A cabazituxel liposomes for increased solubility, enhanced antitumor effect and reduced systemic toxicity. Asian J Pharm Sci 2019;14:658-67.
21. Ali HS, Shah MR, Simjee SU. Design and development of permeation enhancer containing self-nanoemulsifying drug delivery system for cetirizine sodium improved oral pharmacokinetics. J Mol Liq 2019;289:111998.
22. Lanai J M, Zarzuelo A, Maderuelo C. Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. Eur J Pharm Sci 2019;138:105019.
23. Li J, Wang R, Han J. Involvement of metabolism permeability in enhancing the oral bioavailability of curcumin in excipient free solid dispersions co-formed with pipeline. Int J Pharm 2019;561:9-18.
24. Spireas S, Bolton SM. Liquisolid systems and methods of preparing same, U. S. Patent, 5,800,834; 1998.
25. Spireas S, Bolton SM. Liquisolid systems and methods of preparing same, U. S. Patent, 6,096,337; 2000.
26. Spireas S, Sadu SN. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 1998;166:177-88.
27. Nokhodchi A, Javadzadeh Y, Navimipour BJ. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm 2007;341:26-34.
28. Tulsankar SL, Sayyad FJ, Kolap UB. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. J Pharm Res 2013;7:381-8.
29. Lam M, Commandeur D, Nokhodchi A. The crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical performance. Adv Powder Tech 2020;31:1903-14.
30. Lam M, Nokhodchi A, Ghafoorian T. Liqui-pellet: the emerging next-generation oral dosage form which stems from Liquisolid concept in combination with Pelletization technology. AAPS 2019;20:2311.
31. Lam M, Nokhodchi A, Ghafoorian T. Liquisolid system and Liq-mass system are not same. AAPS 2020;22:1:105.
32. Lam M, Nokhodchi A, Ghafoorian T. Optimising the release rate of naproxen liquis-pellet: a new technology for emerging novel oral dosage form. Drug Delivery Trans Res 2020;10:43-58.
33. Ding P, Lu M, Wang D. Liquisolid technique and its applications in pharmaceuticals. Asian J Pharm Sci 2017;12:15-23.
36. Rohera BD, Mamidi KH, Mishra SM. Determination of maximum flowable liquid-loading potential of Neusilin US2 and investigation of compressibility and compactibility of its liquisolid blends with PEG 400. J Drug Delivery Sci Tech 2019;5:4:101-285.
37. Yadav JK, Reddy KD, Jukanti R. Competence of raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation. J Drug Delivery Sci Tech 2015;3:0:232-41.
38. Elkordy AA, Tiong N. Effects of liquisolid formulations on dissolution of naproxen. Eur J Pharm Biopharm 2009;73:373-84.
39. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69:1003.
40. Gubbi SR, Jarag R. Formulation and characterization of atorvastatin calcium liquisolid compacts. Asian J Pharm Sci 2010;5:5:50-60.
41. Elkordy AA, Tan XS, Essa EA. Spironolactone release from liquisolid formulations prepared with capryol 90, solutol HS-15 and kollicoat SR 30 D as non-volatile liquid vehicles. Eur J Pharm Biopharm 2013;83:203-23.
42. Leopold CS, Hentzchel CM, Alnaief M. Enhancement of griseofulvin release from liquisolid compacts. Eur J Pharm Biopharm 2012;80:130-5.
43. Barakat NS, El-Shazil G, Elkhodairy KA. Effect of type and concentration of release-retarding vehicles on the dissolution rate of diltiazem hydrochloride from liquisolid compact. J Drug Delivery Sci Tech 2012;22:189-95.
44. Pezzini BR, Sonaglio D. Liquisolid pellets: mixture experimental design assessment of critical quality attributes influencing the manufacturing performance via extrusion-spheronization. J Drug Delivery Sci Tech 2020;10:16:30.
45. Pezzini BR, Espindola BD. Liquisolid pellets: a pharmaceutical technology strategy to improve the dissolution rate of ritonavir. Saudi J Pharm Sci 2019;27:702-12.
46. Erkoboni DF. Extrusion/spheronization: pharmaceutical pelletization technology; Isaac Ghebre, Vol. 133. Marcel Dekker; 2003. p. 277-318.
47. Mehta KA, Rekhi GS, Parikh DM. Extrusion/spheronization as a granulation technique: Handbook of pharmaceutical granulation technology; Taylor and Francis; 2005. p. 333-60.
48. www.saintytec.com/extruder-spheronizer. [Last accessed on 10 Jul 2020]
49. www.umangpharmatech.com. [Last accessed on 10 Jul 2020]
50. www.industrialextrusionmachinery.com. [Last accessed on 10 Jul 2020]
51. www.spheronizer.com. [Last accessed on 10 Jul 2020]
52. Mehtay J, Nanagude T, Poddar S. Extrusion-spheronization a promising pelletization technique: in-depth review. Asian J Pharm Sci 2016;11:684-99.
53. Gustafsson CL, Johal HK, Newton JM. The influence of water content and drug solubility on the formulation of pellets by extrusion and spheronization. Eur J Pharm Sci 1999;8:147-52.
54. Dukic OA, Vercaut, Kleinebudde P. Production of pellets via extrusion-spheronization without the incorporation of microcrystalline cellulose: a critical review. Eur J Pharm Biopharm 2009;71:38-46.
55. Levis SR, Denay PB. Production and evaluation of size reduced grades of microcrystalline cellulose. Int J Pharm 2001;213:13-24.
56. Rojas J, Correa D. Assessment of the production variables on the pelletization properties of microcrystalline cellulose II (MCCII). Int J Pharm Sci 2017;9:73-80.
57. Donaglio D, Bataille B, Jacob M. Effects of extrusion and formulation parameters on the production of paracetamol-microcrystalline cellulose extrudates. Pharmaceutica Acta Helvetiae 1997;72:69-74.
58. Fielden KE, Newton JM, Rowe RC. Thermal studies on the interaction of water and microcrystalline cellulose. J Pharm Pharmacol 1988;40:674-8.
59. Mishra RV, Paldevar SG, Nandgude TD. An outline of variables in pelletization by extrusion-spheronization. Int J Appl Pharm 2020;12:39-44.
60. Dasheshkiya A, Zouharia G, Ali R. Water-soluble and insoluble polymers as binders for pellet preparation by extrusion-spheronization. J Drug Delivery Sci Tech 2019;49:1-5.
61. Pacheco RM, Souto C, Goyanes A. Co-processed MCC-eudragit e excipients for extrusion-spheronization. Eur J Pharm Biopharm 2011;79:658-63.